A differentiated way to support neuropsychiatry assets across the lifecycle

Osmind actively supports sponsors ranging from top 5 pharma to clinical stage biotechs to neurotechnology companies.

Our projects have included retrospective RWD analyses, fit-for-purpose registries, prospective data capture, data-driven trials recruitment, market research, and commercial engagement (e.g. HCP education, patient identification).

A man in a red tie standing next to a woman in a blue dress.

Making an impact on psychiatry

"Osmind is doing important, much-needed work. I truly believe that we are at an inflection point in our ability to markedly improve outcomes for our patients – both from an improved understanding of novel therapeutics, and our ability to move towards precision medicine."

Husseini K. Manji, M.D., F.R.C.P.C.
Former Global Head of Neuroscience at Janssen Research & Development

“Our collaboration with Osmind offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.”

Nitin Gogtay, M.D.
Chief of Research and Deputy Medical Director, American Psychiatric Association

"We're at a critical juncture in neuropsychiatry. Leveraging real-world evidence can accelerate breakthrough treatment development. Osmind’s platform offers an extremely large source of longitudinal data. I'm excited to work with Osmind to develop more effective, personalized treatments for mental health conditions."

Robert M. Berman, M.D.
Co-founder and former Chief Medical Officer, Biohaven Pharmaceuticals

“Osmind’s approach to unlocking next-generation treatments by leveraging real-world evidence and their digital infrastructure has the potential to meaningfully impact our ability to bring new treatments to patients in dire need. They’ve made incredible progress already.”

Brent Saunders
CEO of Bausch + Lomb; past Chairman, President, and CEO at Allergan

Backed by industry leaders

A close up of a person wearing a suit and tie.

Husseini Manji, MD

Former Global Head of Neuroscience, J&J

Rob Berman, MD

Co-founder and former Chief Medical Officer, Biohaven Pharmaceuticals

A man in a lab coat and tie.

Jeff Leiden, MD, PhD

Executive Chairman, former President and CEO, Vertex Pharmaceuticals

A man in a suit and tie smiling at the camera.

Brent Saunders

CEO, Bausch & Lomb; Former CEO & Chairman, Allergan

Connecting the point-of-care with life sciences innovation

Our software is the
system of record

Our fully-integrated software platform includes an EHR, patient app, practice management system, clinician community, and advanced analytics system

Depth and quality of real-world data

High quality clinical and outcomes data at scale. Structured for research from the point of data generation, e.g. from our library of 50+ outcomes measures

Direct relationship
with clinics

Network of engaged, research-forward clinicians using our software and in our proprietary clinician community

Direct relationship
with patients

Network of engaged patients actively using our software

Accelerate your programs across the development lifecycle

Trusted by leading companies. Below are examples from recent
projects we have conducted.

Translational research

Example: We used RWD to develop novel subtypes of psychiatric conditions for more precise therapeutic targeting

Clinical development

Example: We used RWD to help design clinical trials and recruit patients for studies

Medical affairs, HEOR

Example: We assessed the real-world effectiveness and treatment patterns of novel psychiatric therapies and produced high-impact publications geared towards HCPs and payers

PV, safety studies, REMS

Example: We automated the REMS program and collected high quality, customized safety data on specific psychiatric treatments

Commercial

Example: We conducted market research studies to understand clinician perspectives, educated clinicians about new treatments, and helped them adjust their workflows accordingly (support across the funnel)

What we do

  • RWE
    • Retrospective analyses of EHR-derived RWD
    • Fit-for-purpose registries
    • Prospective data capture
  • Data-driven trials recruitment
  • Market research, physician and patient perspectives (qualitative, quantitative, linkage with RWD)
  • Commercial, HCP engagement and education, patient identification
A group of people sitting around a wooden table.

Featured news & research

Featured Research
May 4, 2021

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings

McInnes, Qian, Gargeya et al. (2021). Psychedelic Therapeutics and Drug Development Conference.

Featured Research
Feb 27, 2021

Psychedelic medicine in child and adolescent psychiatry: an analysis of risks and benefits

Qian and Nattagh (2021). Klingenstein Child Psychiatry Annual Conference.

Featured Update
May 11, 2023

Osmind Announces 2023 Community Advisory Board: Leading Mental Health Clinicians

Featured Research
Aug 15, 2023

The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis

Hietamies, McInnes, Klise et al. (2023). Journal of Affective Disorders.

Featured Research
Jun 20, 2023

Prediction of treatment adherence to ketamine infusion therapy

Kane, Worley, Oldenkamp et al. (2023). Psychedelic Science.

Featured Research
May 15, 2023

CLEO: A Phase 2 Randomized Controlled Adjunctive Treatment Trial with CLE-100 Esketamine Tablet for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants, During The COVID-19 Pandemic

Fava, Berkowitz, Mathew et al. (2023). American Society of Clinical Psychopharmacology Annual Meeting.

Featured Research
Mar 15, 2022

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings

McInnes, Qian, Gargeya et al. (2022). Journal of Affective Disorders.

Featured Research
Oct 18, 2021

REMS in Interventional Psychiatry: A Case Study in Innovation

Qian and MacMillan (2021). REMS Innovation Summit.

Featured Research
May 4, 2021

A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings

McInnes, Qian, Gargeya et al. (2021). Psychedelic Therapeutics and Drug Development Conference.

Learn more about Osmind’s research and real-world evidence
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
logo

If you, or someone you know, is in crisis or needs immediate assistance, please call 911 immediately. To talk to someone now, please call the National Suicide Prevention Lifeline at 1-800-273-8255.

Osmind Inc. © 2024 All Rights Reserved.